Second-line therapy for esophageal cancer

Michael Martin, Ramaswamy Govindan, Daniel Morgensztern

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

Esophageal cancer is a highly lethal disease, with most patients presenting with unresectable or metastatic disease. Since metastatic esophageal cancer is an incurable disease, the goals for chemotherapy are to palliate symptoms and improve survival. Although some patients may achieve symptomatic improvement with the use of standard first-line chemotherapy regimens, response rates are usually low and short lasting. Virtually all patients with metastatic esophageal cancer will develop progressive disease following front-line therapy. With the availability of several chemotherapeutic agents with more tolerable side effects, a number of patients who retain a good performance status after the initial treatment remain candidates for additional therapy. This review summarizes the recent advances in second-line therapy for esophageal cancer.

Original languageEnglish (US)
Pages (from-to)871-876
Number of pages6
JournalExpert Review of Anticancer Therapy
Volume7
Issue number6
DOIs
StatePublished - Jun 1 2007

Fingerprint

Esophageal Neoplasms
Drug Therapy
Therapeutics
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology (medical)

Cite this

Second-line therapy for esophageal cancer. / Martin, Michael; Govindan, Ramaswamy; Morgensztern, Daniel.

In: Expert Review of Anticancer Therapy, Vol. 7, No. 6, 01.06.2007, p. 871-876.

Research output: Contribution to journalReview article

Martin, Michael ; Govindan, Ramaswamy ; Morgensztern, Daniel. / Second-line therapy for esophageal cancer. In: Expert Review of Anticancer Therapy. 2007 ; Vol. 7, No. 6. pp. 871-876.
@article{d8e1afabb12740b687ae1e403fa9075c,
title = "Second-line therapy for esophageal cancer",
abstract = "Esophageal cancer is a highly lethal disease, with most patients presenting with unresectable or metastatic disease. Since metastatic esophageal cancer is an incurable disease, the goals for chemotherapy are to palliate symptoms and improve survival. Although some patients may achieve symptomatic improvement with the use of standard first-line chemotherapy regimens, response rates are usually low and short lasting. Virtually all patients with metastatic esophageal cancer will develop progressive disease following front-line therapy. With the availability of several chemotherapeutic agents with more tolerable side effects, a number of patients who retain a good performance status after the initial treatment remain candidates for additional therapy. This review summarizes the recent advances in second-line therapy for esophageal cancer.",
author = "Michael Martin and Ramaswamy Govindan and Daniel Morgensztern",
year = "2007",
month = "6",
day = "1",
doi = "10.1586/14737140.7.6.871",
language = "English (US)",
volume = "7",
pages = "871--876",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Second-line therapy for esophageal cancer

AU - Martin, Michael

AU - Govindan, Ramaswamy

AU - Morgensztern, Daniel

PY - 2007/6/1

Y1 - 2007/6/1

N2 - Esophageal cancer is a highly lethal disease, with most patients presenting with unresectable or metastatic disease. Since metastatic esophageal cancer is an incurable disease, the goals for chemotherapy are to palliate symptoms and improve survival. Although some patients may achieve symptomatic improvement with the use of standard first-line chemotherapy regimens, response rates are usually low and short lasting. Virtually all patients with metastatic esophageal cancer will develop progressive disease following front-line therapy. With the availability of several chemotherapeutic agents with more tolerable side effects, a number of patients who retain a good performance status after the initial treatment remain candidates for additional therapy. This review summarizes the recent advances in second-line therapy for esophageal cancer.

AB - Esophageal cancer is a highly lethal disease, with most patients presenting with unresectable or metastatic disease. Since metastatic esophageal cancer is an incurable disease, the goals for chemotherapy are to palliate symptoms and improve survival. Although some patients may achieve symptomatic improvement with the use of standard first-line chemotherapy regimens, response rates are usually low and short lasting. Virtually all patients with metastatic esophageal cancer will develop progressive disease following front-line therapy. With the availability of several chemotherapeutic agents with more tolerable side effects, a number of patients who retain a good performance status after the initial treatment remain candidates for additional therapy. This review summarizes the recent advances in second-line therapy for esophageal cancer.

UR - http://www.scopus.com/inward/record.url?scp=34347238919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347238919&partnerID=8YFLogxK

U2 - 10.1586/14737140.7.6.871

DO - 10.1586/14737140.7.6.871

M3 - Review article

VL - 7

SP - 871

EP - 876

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 6

ER -